Deferasirox
Mostrando 1-8 de 8 artigos, teses e dissertações.
-
1. Protective effects of deferasirox and N-acetyl-L-cysteine on iron overload-injured bone marrow
Using an iron overload mouse model, we explored the protective effect of deferasirox (DFX) and N-acetyl-L-cysteine (NAC) on injured bone marrow hematopoietic stem/progenitor cells (HSPC) induced by iron overload. Mice were intraperitoneally injected with 25 mg iron dextran every 3 days for 4 weeks to establish an iron overload (Fe) model. DFX or NAC were co-
Braz J Med Biol Res. Publicado em: 19/10/2017
-
2. Deferasirox-induced urticarial vasculitis in a patient with myelodysplastic syndrome
Abstract Deferasirox is an iron chelator agent used in the treatment of diseases with iron overload, such as thalassemia and myelodysplastic syndrome. Although the majority of adverse reactions of deferasirox involve gastrointestinal symptoms and increase in serum creatinine and transaminases, skin rashes, such as maculopapular and urticarial eruptions, have
An. Bras. Dermatol.. Publicado em: 2017
-
3. Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion
In the absence of an iron chelating agent, patients with beta-thalassemia on regular transfusions present complications of transfusion-related iron overload. Without iron chelation therapy, heart disease is the major cause of death; however, hepatic and endocrine complications also occur. Currently there are three iron chelating agents available for continuo
Rev. Bras. Hematol. Hemoter.. Publicado em: 2013
-
4. Boletim brasileiro de avaliação de tecnologias em saúde: deferasirox para o tratamento da sobrecarga de ferro. / Brazilian bulletin for health technology assessment: deferasirox for iron overload
Objetivo: Avaliar a evidência de eficácia e segurança do deferasirox para o tratamento da sobrecarga de ferro relacionada à betatalassemia, doença falciforme e síndrome mielodisplásica, em comparação a outros quelantes de ferro disponíveis no Brasil (desferroxamina e deferiprona). Método: Para síntese da evidência foi realizada busca por relató
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 22/02/2011
-
5. Sobrecarga e quelação de ferro na anemia falciforme
Pacientes cronicamente transfundidos desenvolvem sobrecarga de ferro que ocasiona lesão orgânica e morte. Nos últimos trinta anos, pacientes com sobrecarga de ferro transfusional dependem de infusões noturnas de desferroxamina para quelação de ferro. Apesar da dramática melhora da expectativa de vida na era da desferroxamina para pacientes com anemias
Revista Brasileira de Hematologia e Hemoterapia. Publicado em: 2007-09
-
6. Tratamento de suporte e quelação de ferro em pacientes com síndromes mielodisplásicas
As síndromes mielodisplásicas (SMD) são um grupo heterogêneo de distúrbios hematológicos que ocorrem mais freqüentemente em pacientes idosos e que cursa, na maioria dos casos, com anemia crônica dependente de transfusão de hemoderivados. Conseqüentemente, muitos destes pacientes passam a apresentar sobrecarga de ferro, que pode levar a danos tecidu
Revista Brasileira de Hematologia e Hemoterapia. Publicado em: 2006-09
-
7. Deferasirox pharmacokinetics in patients with adequate versus inadequate response
Tens of thousands of transfusion-dependent (eg, thalassemia) patients worldwide suffer from chronic iron overload and its potentially fatal complications. The oral iron chelator deferasirox has become commercially available in many countries since 2006. Although this alternative to parenteral deferoxamine has been a major advance for patients with transfusio
American Society of Hematology.
-
8. Tobramycin and FDA-Approved Iron Chelators Eliminate Pseudomonas aeruginosa Biofilms on Cystic Fibrosis Cells
The ability of Pseudomonas aeruginosa to form antibiotic-resistant biofilms is thought to account for the inability of current therapies to resolve bacterial infections in the lungs of patients with cystic fibrosis (CF). We recently described a system in which highly antibiotic-resistant P. aeruginosa biofilms grow on human CF airway epithelial cells, and us
American Thoracic Society.